Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
作者信息
Chew Ka Lip, Tay Michelle K L, Cheng Bernadette, Lin Raymond T P, Octavia Sophie, Teo Jeanette W P
机构信息
National University Hospital, Department of Laboratory Medicine, Singapore, Singapore
National University Hospital, Department of Laboratory Medicine, Singapore, Singapore.
出版信息
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00414-18. Print 2018 Aug.
Abstract
摘要
相似文献
1
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.氨曲南-阿维巴坦联合用药恢复了产双碳青霉烯酶肠杆菌科细菌对氨曲南的敏感性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00414-18. Print 2018 Aug.
2
Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.马德里（西班牙）一家三级医院产多种碳青霉烯酶肠杆菌科细菌的发生：一个新的流行病学情况。
J Glob Antimicrob Resist. 2024 Sep;38:281-291. doi: 10.1016/j.jgar.2024.06.012. Epub 2024 Jul 10.
3
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
4
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.采用小鼠大腿感染模型，对美罗培南、头孢吡肟或氨曲南与新型β-内酰胺酶抑制剂那库巴坦联合用药，针对耐碳青霉烯类和/或产碳青霉烯酶的肺炎克雷伯菌和大肠埃希菌进行药效学评价。
Int J Antimicrob Agents. 2021 May;57(5):106330. doi: 10.1016/j.ijantimicag.2021.106330. Epub 2021 Mar 28.
5
Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.从一组经头孢他啶、头孢洛林或氨曲南-阿维巴坦联合检测的耐碳青霉烯类肠杆菌科细菌中鉴定出异常的大肠杆菌PBP 3插入序列。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00389-17. Print 2017 Aug.
6
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.头孢他啶/阿维巴坦、美罗培南/沃巴坦和亚胺培南/雷利巴坦对美国医院碳青霉烯酶阴性碳青霉烯类耐药肠杆菌科分离株的活性。
Int J Antimicrob Agents. 2021 Nov;58(5):106439. doi: 10.1016/j.ijantimicag.2021.106439. Epub 2021 Sep 20.
7
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.在法国一项前瞻性区域间调查中收集的碳青霉烯不敏感肠杆菌分离株的分子特征以及对新型头孢他啶-阿维巴坦和氨曲南-阿维巴坦联合制剂的敏感性
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
8
In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.体外和体内研究头孢他啶/阿维巴坦和氨曲南单独或联合用药对同时产 mcr-9、丝氨酸和金属β-内酰胺酶的碳青霉烯类耐药肠杆菌科复合菌的活性。
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1309-1318. doi: 10.1007/s10096-024-04841-8. Epub 2024 May 3.
9
Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.荷兰产碳青霉烯酶肠杆菌科细菌的分子特征；2014-2018 年全国实验室监测结果。
Clin Microbiol Infect. 2020 Oct;26(10):1412.e7-1412.e12. doi: 10.1016/j.cmi.2020.01.027. Epub 2020 Feb 5.
10
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
引用本文的文献
1
Upholding the fundamental values of infection prevention and antimicrobial stewardship in the current political climate.在当前政治环境下秉持感染预防和抗菌药物管理的基本价值观。
Antimicrob Steward Healthc Epidemiol. 2025 Apr 23;5(1):e97. doi: 10.1017/ash.2025.67. eCollection 2025.
2
Multispecies emergence of dual carbapenemase-producing Enterobacterales recovered from invasive infections in Chile.从智利侵袭性感染中分离出的产双碳青霉烯酶肠杆菌科细菌的多物种出现情况。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0120524. doi: 10.1128/aac.01205-24. Epub 2024 Dec 5.
3
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.在 COVID-19 时代，产碳青霉烯酶肠杆菌科细菌中多碳青霉烯酶的产生情况以及包含头孢地尔、头孢他啶-阿维巴坦、美罗培南-沃巴坦和氨曲南的联合用药的体外活性。
Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):573-580. doi: 10.1007/s10096-022-04408-5. Epub 2022 Jan 21.
4
Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant .头孢他啶-阿维巴坦和氨曲南-阿维巴坦对耐碳青霉烯类血流感染的抗菌活性及最佳治疗方案
Front Pharmacol. 2021 Dec 14;12:771910. doi: 10.3389/fphar.2021.771910. eCollection 2021.
5
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections.氨曲南与新旧β-内酰胺酶抑制剂联合对产金属β-内酰胺酶和超广谱β-内酰胺酶的革兰阴性临床分离株的抗菌活性：治疗复杂感染的可能选择
Antibiotics (Basel). 2021 Nov 3;10(11):1341. doi: 10.3390/antibiotics10111341.
6
Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019.检测和鉴定目标性碳青霉烯类耐药的卫生保健相关性威胁：来自抗生素耐药实验室网络的研究结果，2017 年至 2019 年。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0110521. doi: 10.1128/AAC.01105-21. Epub 2021 Sep 27.
7
Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam.成功治疗泛耐药肺炎克雷伯菌引起的感染性心内膜炎：头孢他啶-阿维巴坦联合氨曲南。
Sci Rep. 2021 May 6;11(1):9684. doi: 10.1038/s41598-021-89255-8.
8
Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive .新型特异性金属β-内酰胺酶抑制剂ANT2681可将美罗培南对NDM阳性菌的活性恢复至临床有效水平。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00203-21.
9
Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Infections.产碳青霉烯酶感染治疗选择的现状与未来展望
Microorganisms. 2021 Mar 31;9(4):730. doi: 10.3390/microorganisms9040730.
10
Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.产金属β-内酰胺酶肠杆菌科细菌的治疗选择
Infect Drug Resist. 2021 Jan 18;14:125-142. doi: 10.2147/IDR.S246174. eCollection 2021.
本文引用的文献
1
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.氨曲南-阿维巴坦和对照药物对当代（2016 年）临床肠杆菌科分离株的抗菌活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01856-17. Print 2018 Jan.
2
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.沃博巴坦：β-内酰胺酶抑制谱及耐药机制对肠杆菌科活性的影响。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01443-17. Print 2017 Nov.
3
Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.2012 年至 2015 年，40 个国家临床实验室分离的肠杆菌科和铜绿假单胞菌对头孢他啶-阿维巴坦的活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00472-17. Print 2017 Sep.
4
Clinical and Molecular Epidemiology of Carbapenem-Resistant Enterobacteriaceae Among Adult Inpatients in Singapore.新加坡成年住院患者中耐碳青霉烯肠杆菌科的临床和分子流行病学。
Clin Infect Dis. 2017 May 15;64(suppl_2):S68-S75. doi: 10.1093/cid/cix113.
5
Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health.新德里金属β-内酰胺酶（NDM）的结构、遗传学及全球传播：对公共卫生的威胁
BMC Microbiol. 2017 Apr 27;17(1):101. doi: 10.1186/s12866-017-1012-8.
6
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.β-内酰胺酶抑制剂瓦博巴坦与美罗培南联合使用对产丝氨酸碳青霉烯酶肠杆菌科细菌的作用
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8. doi: 10.1128/AAC.00711-16. Print 2016 Sep.
7
Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.blaKPC在肺炎克雷伯菌以外的细菌物种中的全球传播以及对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的体外敏感性
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.
8
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.β-内酰胺酶抑制剂复方制剂对抗多重耐药革兰氏阴性病原体的卷土重来。
Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Epub 2015 Sep 25.
9
In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.头孢他啶-阿维巴坦、氨曲南-阿维巴坦以及一组较老和当代抗菌药物对产碳青霉烯酶革兰氏阴性杆菌的体外活性
Antimicrob Agents Chemother. 2015 Dec;59(12):7842-6. doi: 10.1128/AAC.02019-15. Epub 2015 Sep 21.
10
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.氨曲南-阿维巴坦对2012年和2013年全球革兰氏阴性病原菌菌株集的体外活性
Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.
Zotero 插件